See full prescribing information for complete boxed warning.
When pregnancy is detected, discontinue lisinopril and hydrochlorothiazide as soon as possible.
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS; Fetal Toxicity.
Lisinopril and hydrochlorothiazide tablet USP combines an angiotensin converting enzyme inhibitor, lisinopril, and a diuretic, hydrochlorothiazide.
Lisinopril, a synthetic peptide derivative, is an oral long-acting angiotensin converting enzyme inhibitor.
Lisinopril and hydrochlorothiazide tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
These fixed-dose combinations are not indicated for initial therapy (see
DOSAGE AND ADMINISTRATION).
In using lisinopril and hydrochlorothiazide tablets USP, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See
In considering use of lisinopril and hydrochlorothiazide tablets USP, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in black than in nonblack patients. (See
Published Studies Related to Lisinopril and Hydrochlorothiazide (Lisinopril / Hydrochlorothiazide)
Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension. [2006.08]
We investigated the effects of aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril on left ventricular mass (LVM) index and arterial stiffness in hypertensive type II diabetic individuals. Seventy hypertensive type II diabetic individuals were treated with three antihypertensive strategies in a randomized, double-blind, double-dummy design...
Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. [2006.03]
The aim of this study was to compare the effects of telmisartan/hydrochlorothiazide (HCTZ) vs lisinopril/HCTZ combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. A total of 160 patients, 76 men and 84 women, aged 61-75 years, with sitting diastolic blood pressure (DBP)>90 mmHg and <110 mmHg and systolic blood pressure (SBP)>140 mmHg were randomized to receive temisartan 80 mg/HCTZ 12.5 mg o.d...
Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. [2005.06]
We investigated the effects of aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril on urinary albumin excretion, endothelial function and inflammatory activity in hypertensive type II diabetic individuals. A total of 70 hypertensive type II diabetic individuals were treated with three antihypertensive strategies in a randomized, double-blind, double-dummy design...
Clarithromycin suspension: bioequivalence studies on two different strengths. [2004.09]
Two studies were performed in different groups of volunteers, with the aim to prove the bioequivalence of test (Klaromin) and reference clarithromycin (CAS 81103-11-9) suspensions containing in 5 mL either 125 mg (study 1) or 250 mg (study 2) of the drug, administered as an oral dose of 10 mL...
Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. [2004.06]
BACKGROUND: The goal of antihypertensive therapy is to provide good blood pressure (BP) control without eliciting adverse effects. OBJECTIVE: This study compared the risk-benefit profile of the angiotensin II receptor blocker valsartan with that of the angiotensin-converting enzyme inhibitor lisinopril in patients with mild to severe hypertension. The primary objective was to show that the equipotent BP-lowering effect of the valsartan-based treatment is accompanied by a better tolerability profile... CONCLUSIONS: Valsartan and lisinopril were both highly effective in controlling BP in these patients with mild to severe hypertension, but valsartan was associated with a significantly reduced risk for AEs, especially cough.
Clinical Trials Related to Lisinopril and Hydrochlorothiazide (Lisinopril / Hydrochlorothiazide)
Bioequivalence Study of Two Formulations of 10 mg Lisinopril Tablet Under Fasting Condition [Completed]
The present study was conducted to find out whether the bioavailability of 10 mg lisinopril
tablets produced by PT Dexa Medica was equivalent to the tablets produced by the innovator
(Zestril« 10 mg, PT Boehringer Ingelheim Indonesia, Indonesia, under license from Astra
Zeneca UK Ltd.)
Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure [Completed]
Randomized, double-blind, parallel group, multicenter study of subjects with Stage 1 or 2
essential hypertension who are not at target blood pressure (<140/90mmHg) at Baseline.
Subjects will be randomized to receive either carvedilol CR + lisinopril or lisinopril +
placebo. Subjects will be uptitrated over a 6 week period until target blood pressure
(<140/90mmHg) is met. The primary objective of the study is to compare the proportion of
subjects who achieve target blood pressure after 6 weeks of treatment.
Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects [Completed]
To assess if oral nizatidine or lisinopril alone and in combination will increase heme
oxygenase 1 (HO-1) protein concentration and activity compared to placebo in healthy
Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant [Completed]
The drug lisinopril is approved by the U. S. Food and Drug Administration for the treatment
of high blood pressure, heart failure, and acute heart attacks in adult patients. In
children over 6 years of age, lisinopril is approved for the treatment of high blood
pressure. Lisinopril is in a group of medications called angiotensin-converting enzyme
inhibitors (ACE). ACE inhibitors such as lisinopril work by decreasing certain chemicals
that tighten the blood vessels so blood flows more smoothly and the heart can pump blood
There is some information available about how children with high blood pressure absorb,
distribute, metabolize, and eliminate lisinopril (this information about medication
processing by the body is called pharmacokinetic data). However, there is no information
about how children with high blood pressure who have received a kidney transplant process
lisinopril. In addition to decreasing blood pressure, investigators believe that lisinopril
may help kidney transplants work longer by reducing the activity of chemicals made by cells
in kidney transplants that can lead to inflammation and injury. Such benefits have not been
found with another group of blood pressure medications called calcium channel blockers,
which are the most commonly used medication group to control high blood pressure in children
after a kidney transplant. A clinical trial will be conducted in the future to compare which
medication group helps kidney transplants in children last longer. To guide the selection of
the best dose to test in future studies, investigators in this study will try to determine
the safety profile, dose tolerability, and pharmacokinetics of lisinopril in children and
adolescents (2-17 years of age) who have received a kidney transplant and have high blood
The Effect and Safety of Lisinopril in Non-hypertensive Men With Infertility From Low Sperm Count [Completed]
This study was conceived in order to explain what the investigators previously observed
suggesting that lisinopril, a drug normally used to treat patients with high blood pressure
and heart failure, may be effective in treating infertile men with low sperm count. The
investigators hypothesized, therefore, that the drug will not only improve sperm quantity
and quality but also increase the fertility in such patients. The investigators first of all
reviewed the results of previously published investigations and found out that there was
only a few previous studies done in humans. with this class of drugs. Besides, the methods
used in conducting most of those studies have been so faulted that the results cannot be
trusted to be showing the true picture. The investigators looked at the various faults
pointed out with respect to the their design and conduct and took care of them while
designing the investigators own study. This was an attempt to provide more credible answers
to the question of whether lisinopril, and possibly other drugs of similar mode of action,
can be useful in rectifying the problem of infertility caused by low sperm count and , if
so, whether it will be safe to use it in people who do not have high blood pressure or heart
failure. In order to achieve this the investigators studied 33 patients with sperm of low
cell concentration, low percentage of motile cells and high percentage of abnormal cells
from no known cause. The patients were randomly allocated to receive either lisinopril 2. 5mg
daily (17 patients) or daily placebo (16 patients)and their sperm characteristics were
examined at intervals, starting from the beginning of the study until when it ended 282
weeks later. The patients were also monitored for adverse events throughout the period. The
data form all the patients that took part in the random allocation of treatments at the
beginning of the study were included in the analysis that followed, irrespective of whether
they completed the study or not.
Reports of Suspected Lisinopril and Hydrochlorothiazide (Lisinopril / Hydrochlorothiazide) Side Effects
Renal Failure Acute (22),
Swollen Tongue (18),
Drug Ineffective (14),
Vomiting (13), more >>
Page last updated: 2007-02-12